Answers are grounded in this paper and cite their sources.
Systematic review evaluates the survival benefits of immunotherapy combined with chemoradiotherapy for patients with unresectable esophageal cancer, suggesting significant improvements.
e16137 Background: Concurrent chemoradiotherapy (CCRT) remains the standard treatment for nonsurgical esophageal cancer (EC); however, the prognosis remains poor. The clinical benefits of the combination of immunotherapy with CCRT for unresectable EC remain controversial. Therefore, we performed a systematic review and meta-analysis of published studies to evaluate the potential benefits of different combined immunotherapeutic strategies based on CCRT for patients with unresectable EC. Methods: We employed single-arm, pairwise and network meta-analysis methods to analyze the overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and safety of several combined treatment strategies based on CCRT. Results: 28 single-arm trials and 34 controlled trials involving a total of 8104 participants were included. Single-arm meta-analysis have demonstrated that CCRT plus consolidation immunotherapy (CCRT-IO) has the highest 1-year OS rate of 85.7% (95%CI 73.6-97.8, I² = 86.4%) and 2-year OS rate of 67.3% (95%CI 58.8-75.9, I² = 35.2%). However, due to the limited number of available studies, pairwise and network meta-analyses could not be performed. The pairwise meta-analysis showed that, compared with CCRT alone, induction immunochemotherapy plus CCRT (ICT-CCRT) had significantly improved OS (0.49, 95%CI 0.32-0.74, I² = 0.0%) and PFS (HR 0.54, 95%CI 0.37-0.79, I² = 0.0%). The network meta-analysis showed that ICT-CCRT yielded the best OS and PFS results, with substantial benefits over CCRT alone (HR 0.73, 95% CI 0.58-0.92; HR 0.77, 95% CI 0.60-0.98). Conclusions: The study revealed that ICT-CCRT significantly improves patient survival compared to CCRT. CCRT-IO has also been associated with a survival benefit, achieving the highest 1- and 2-year OS rates in single-arm studies. Due to the limited number of available studies, a statistical comparison of survival benefits between CCRT-IO and ICT-CCRT was not feasible.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: